Figure 2: Controlled release of biologically active immunomodulators from cryogels. | Nature Communications

Figure 2: Controlled release of biologically active immunomodulators from cryogels.

From: Injectable cryogel-based whole-cell cancer vaccines

Figure 2

(a) Encapsulation efficiency of GM-CSF (detected by ELISA) in alginate cryogels following polymerization, washing and sterilization; GM-CSF was incorporated in the presence (+) or absence (−) of CpG ODN in the cryogel. (b) Cumulative release of GM-CSF from alginate cryogels over a period of 6 weeks in vitro; blue: cryogels containing only 1.5 μg GM-CSF, red: cryogels containing 1.5 μg GM-CSF+50 μg CpG ODN. (c) Encapsulation efficiency of CpG ODN (detected by an OliGreen assay) in alginate cryogels post polymerization, washing and sterilization; CpG ODN was incorporated in the presence (+) or absence (−) of GM-CSF in the cryogel. (d) Cumulative release of CpG ODN from alginate cryogel matrices over a period of 6 weeks; green: cryogels containing only 50 μg CpG ODN, red: cryogels containing 1.5 μg GM-CSF+50 μg CpG ODN. Values represent mean and s.d. (n=5). Differences between groups were statistically significant. Data were analysed using Student’s t-test, *P<0.05, **P<0.01.

Back to article page